Калкулатор за Thymosin Alpha-1

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (often abbreviated Tα1) is a synthetic peptide composed of 28 amino acids and carrying an acetylated N-terminus. It corresponds to a naturally occurring fragment of the precursor protein prothymosin alpha, which is produced in the thymus gland. The thymus is the central organ for the maturation of T-lymphocytes, and the thymic factors it releases govern essential steps of adaptive immunity. Thymosin Alpha-1 was first isolated in the 1970s from the thymic extract Thymosin Fraction 5 and has since become one of the most intensively studied immune-modulating peptides.

Unlike repair peptides such as BPC-157 or TB-500, whose research focus lies in tissue healing and angiogenesis, Thymosin Alpha-1 is discussed primarily in the context of immune regulation. In preclinical and clinical models it has been studied in connection with strengthening the cell-mediated immune response, normalizing immune function under conditions of immunosuppression, and moderating excessive inflammatory reactions. Approved in several countries as a pharmaceutical under the brand name Zadaxin, Thymosin Alpha-1 is used there as an adjunct in chronic hepatitis B and C and as an immune-supporting agent. In the European Union and most Western markets it holds no marketing authorization as a medicine and therefore remains strictly within the research domain.

An important point of orientation: Thymosin Alpha-1 and Thymosin Beta-4 (TB-500) share only the historical name component "thymosin," because both were originally isolated from the same thymic fraction. Structurally and functionally they are entirely different. Thymosin Beta-4 is an actin-binding repair peptide, while Thymosin Alpha-1 is an immune modulator with no meaningful direct repair function. This distinction is critical for any research planning.

Mechanisms of Action

Thymosin Alpha-1 does not act through a single receptor but produces a broad spectrum of immunoregulatory effects. It behaves more like a biological switch that strengthens or rebalances the immune response depending on the starting state. The principal mechanisms characterized in research include:

• Maturation and differentiation of T-lymphocytes: Thymosin Alpha-1 promotes the development of immature progenitor cells into functional T-cells. It particularly supports the maturation of CD4-positive helper cells and CD8-positive cytotoxic T-cells, which are responsible for the targeted defense against virus-infected and abnormal cells.
• Activation of dendritic cells via Toll-like receptors: Tα1 interacts with Toll-like receptors, primarily TLR2 and TLR9, on dendritic cells and monocytes. This TLR signaling enhances antigen presentation and bridges the innate and adaptive arms of immunity.
• Modulation of the cytokine environment: In preclinical models, Thymosin Alpha-1 increases the production of interferon-gamma, interleukin-2, and other Th1-oriented cytokines. This shift toward a Th1 response favors cell-mediated immunity against intracellular pathogens.
• Enhancement of natural killer cell activity: Research has observed increased cytotoxic activity of NK cells, which serve as a first line of defense against virus-infected and tumor-like altered cells.
• Regulation of immune balance: Thymosin Alpha-1 acts in a context-dependent manner. Where immune function is suppressed it supports the immune response; where inflammation is excessive it can act as a regulator, helping to restore immune homeostasis.
• Reduction of oxidative stress and immune-cell apoptosis: Preclinical data suggest that Tα1 may reduce the premature programmed cell death of lymphocytes and mitigate oxidative burden within the immune system.

Dosage Calculation

Thymosin Alpha-1 is dosed in milligrams in research and is typically administered subcutaneously. Dosing is guided by the specific research question; most protocols use a fixed dose without an ascending titration.

Standard Dosing Parameters

• Conservative dose: 0.8 mg (800 mcg) per injection
• Standard dose: 1.6 mg (1,600 mcg) per injection, corresponding to a common vial content
• Higher range: 3.2 mg (3,200 mcg) per injection
• Frequency: 2 to 7 times per week, depending on the research protocol
• Typical syringe: 0.5 mL or 1 mL insulin syringe (29 to 31 gauge)

Example Calculation: 10 mg Vial with 1 mL BAC Water

Thymosin Alpha-1 is commonly supplied in 10 mg vials. Reconstituting a 10 mg vial with 1 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL).

• 0.8 mg dose: 800 ÷ 10000 = 0.08 mL (8 units on a U100 syringe)
• 1.6 mg dose: 1600 ÷ 10000 = 0.16 mL (16 units)
• 3.2 mg dose: 3200 ÷ 10000 = 0.32 mL (32 units)

At a standard dose of 1.6 mg, a 10 mg vial provides six full doses plus a remainder. Because vial sizes and reconstitution volumes vary widely, the precise injection volume should be determined individually for each protocol. The Thymosin Alpha-1 calculator above computes the exact volume for any combination of vial size, BAC water amount, and target dose.

Reconstitution

Thymosin Alpha-1 is supplied as a lyophilized, freeze-dried powder in sealed vials and must be dissolved before use. For multi-dose vials, bacteriostatic water (BAC water) is the appropriate diluent, because its 0.9 percent benzyl alcohol content inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is suitable only for vials that will be fully consumed in a single session.

Step-by-Step Reconstitution Protocol

1. Gather supplies: the Thymosin Alpha-1 vial, a vial of BAC water, alcohol swabs, a sterile draw needle (18 to 21 gauge), and the insulin syringe for injection.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa afterward.
3. Draw the desired volume of BAC water into the draw syringe, for example 1 mL for a 10 mg vial to obtain a concentration of 10 mg/mL.
4. Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than directly onto the powder cake. Spraying diluent straight onto the powder can shear delicate peptide bonds and damage the molecule.
5. Push the plunger slowly so the BAC water runs down the inside wall of the vial and gently wets the powder from below.
6. Carefully roll or gently swirl the vial between your palms until the powder has dissolved completely. The finished solution should be clear and colorless. Never shake or vortex the vial, as mechanical stress can denature the peptide.
7. Label the vial with the reconstitution date and concentration, for example "Thymosin Alpha-1 10 mg/mL, reconstituted [date]."

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage; in this state Thymosin Alpha-1 is stable for 24+ months. Short-term storage at 2 to 8°C in a refrigerator is acceptable for several weeks. Protect from light and moisture.
• Reconstituted solution: Always store in the refrigerator at 2 to 8°C. Solutions prepared with BAC water are stable for approximately 28 to 30 days. Keep the vial upright and away from light, and discard it after the usable window regardless of remaining volume.
• Do not freeze reconstituted peptide. Freeze-thaw cycles cause protein aggregation and a loss of biological activity. Once reconstituted, the vial must remain refrigerated throughout.
• Transport: For any travel lasting more than one to two hours, use an insulated cooler with an ice pack. Commercial insulated medication pouches maintain 2 to 8°C for 24 to 48 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

Thymosin Alpha-1 shows a consistently favorable tolerability profile across numerous preclinical and clinical investigations. As a fragment of an endogenous thymic protein, it has not produced organ toxicity, mutagenic effects, or hormonal disruption even at higher doses. Because it is an immune-modulating peptide, however, some aspects warrant particular attention.

Commonly Reported Observations

• Mild redness, transient swelling, or brief discomfort at the injection site. These local reactions resolve within a few hours in most users; rotating injection sites minimizes localized irritation.
• Occasional mild fatigue or a flu-like feeling during the first days of a protocol, likely related to the activation of the immune response, which usually subsides quickly.
• Occasional mild headache or brief chills after injection, which typically resolve on their own.

Less Common or Theoretical Concerns

• Autoimmune predisposition: Because Thymosin Alpha-1 strengthens cell-mediated immunity, it could theoretically promote an overactive immune response in individuals with existing autoimmune disease. Particular caution is warranted in such contexts.
• Interaction with immunosuppressive medication: When taken alongside immunosuppressants, for example after organ transplantation, the immune-activating action of Tα1 could theoretically counteract that therapy. This interaction is not well characterized.
• Allergic reactions: As with any injectable peptide, rare hypersensitivity reactions are possible. Persistent or pronounced local reactions should be treated as a possible sign of sensitization.

Contraindications

• Existing autoimmune disease without specialist supervision
• Post organ transplantation status or ongoing immunosuppressive therapy
• Pregnancy and breastfeeding, as robust safety data are lacking
• Known hypersensitivity to any component of the preparation

In the published literature, few serious adverse events have been reported in approved clinical applications. Because Thymosin Alpha-1 is not authorized as a medicine in the EU and is supplied strictly for research purposes, consultation with a qualified healthcare professional before any use is strongly recommended.

Combinations and Stacks

Thymosin Alpha-1 plus BPC-157

Thymosin Alpha-1 covers a mechanism the classic repair peptides do not address: immune regulation. In research contexts it is therefore occasionally considered alongside BPC-157. While BPC-157 drives angiogenesis, collagen synthesis, and gastrointestinal healing, Thymosin Alpha-1 addresses the immunological component of recovery and stress. The two peptides act on fundamentally different axes and have essentially no mechanistic overlap.

Thymosin Alpha-1 and the Thymosin Beta-4 Misconception

Because of the shared name component, Thymosin Alpha-1 and TB-500 (Thymosin Beta-4) are frequently mentioned side by side in the research literature. Functionally, however, they are clearly distinct: TB-500 is an actin-binding repair and migration peptide, while Thymosin Alpha-1 is a pure immune modulator. Anyone considering both within a protocol should treat them as two independent tools serving different questions, not as related substances with similar effects.

Thymosin Alpha-1 plus KPV

For research questions around inflammation modulation, Thymosin Alpha-1 is sometimes considered alongside KPV. KPV is a short anti-inflammatory tripeptide that dampens pro-inflammatory signaling pathways, while Thymosin Alpha-1 regulates immune balance at the level of T-cell maturation. Both address the immune system from complementary angles: KPV more by dampening, Thymosin Alpha-1 more by rebalancing.

Thymosin Alpha-1 is not currently listed in the BergdorfBio range. Available peptides can be found in the BergdorfBio product catalog. All products are offered strictly for research purposes.

Frequently Asked Questions

Is Thymosin Alpha-1 the same as Thymosin Beta-4 or TB-500?

No. Both peptides carry the name component "thymosin" because they were historically isolated from the same thymic fraction, but they are structurally and functionally entirely different. Thymosin Alpha-1 is an immune-modulating peptide of 28 amino acids; Thymosin Beta-4 is an actin-binding repair peptide of 43 amino acids. They are not interchangeable.

How is Thymosin Alpha-1 administered?

In research, Thymosin Alpha-1 is usually injected subcutaneously, that is into the tissue just below the skin, most often in the abdominal area. Subcutaneous injection allows steady absorption. There is no reliable oral form, since the peptide would be broken down in the gastrointestinal tract.

How often is Thymosin Alpha-1 dosed in protocols?

Frequency ranges from twice to seven times per week depending on the research protocol. More intensive protocols use daily or near-daily dosing over a limited period, while others rely on two to three injections per week across longer cycles. An ascending titration is generally not required.

Does Thymosin Alpha-1 affect hormone levels?

No. Thymosin Alpha-1 does not bind to hormone receptors and does not interact with the hypothalamic-pituitary axis, thyroid function, or sex hormones. It acts purely as an immune modulator, so no post-cycle therapy is required.

How long does a typical Thymosin Alpha-1 cycle last?

Research protocols frequently run over four to eight weeks, and longer in some questions. Because Thymosin Alpha-1 modulates immune balance, continuous use over many months without a break is uncommon in research. Specific cycle lengths depend entirely on the study design in question.

Is Thymosin Alpha-1 an approved medicine?

In some countries Thymosin Alpha-1 is approved as a prescription medicine under the brand name Zadaxin, for example as an adjunct in certain viral infections. In the European Union it holds no marketing authorization as a medicine. The material described here is supplied strictly for research purposes and is not intended for human use.

Is Thymosin Alpha-1 relevant to sports drug testing?

Thymosin Alpha-1 is not a growth factor and not an anabolic hormone. It does not fall into the same category as performance-enhancing peptides. Athletes subject to anti-doping regulations should nonetheless always check the current WADA prohibited list, since classifications can change.

Can Thymosin Alpha-1 be mixed with other peptides?

Although some users combine multiple peptides immediately before injection, it is safer to reconstitute each peptide individually and inject them separately. Combined stability in solution is often not characterized, and separate injections eliminate dosing errors and undesirable in-solution interactions.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. Thymosin Alpha-1 is not an approved medicine in the European Union and is supplied strictly for research use. Nothing on this page constitutes medical advice, a diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before considering any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.